Delving into the Latest Updates on Abacavir Sulfate/Lamivudine/Zidovudine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Abacavir (as sulfate)/Lamivudine/Zidovudine, Abacavir/lamivudine/zidovudine, Abacavir/zidovudine/lamivudine

+ [8]

Target

RT

Action

inhibitors

Mechanism

RT inhibitors(Viral reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

ViiV Healthcare Ltd.

Active Organization

ViiV Healthcare UK Ltd.ViiV Healthcare BV

Inactive Organization

ViiV Healthcare Co.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (14 Nov 2000),

HIV Infections

RegulationAccelerated Approval (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC32H42N14O8S

InChIKeyYATVXQQJLKIPSI-SBGMWXOCSA-N

CAS Registry364057-50-1

Aicardi-Goutières syndrome (AGS) is a disease of children, particularly affecting the brain and the skin. There is a close link between AGS and increased amounts of a chemical called interferon. Normally humans only produce interferon when they are infected with a virus. In AGS, there is no viral infection. Instead, the cells in the cells of affected patients are confused into thinking that their own genetic material is coming from a virus. As a result they produce interferon all the time, which acts as a poison that damages the cells. The Investigators wish to treat AGS patients with drugs called reverse transcriptase inhibitors (RTIs), used to fight the HIV-1 virus that causes AIDS. The investigators will monitor the effect of treatment on interferon levels, and look at other markers which might give us clues to how the drugs are working. The trial is funded by the Medical Research Council, and involves experts based in Edinburgh, Birmingham, Manchester and Great Ormond Street Hospital.

Start Date24 Aug 2022

Sponsor / Collaborator

The University of Edinburgh

[+2]

EUCTR2012-000198-21-ES

/ CompletedPhase 4IIT

A multicenter randomised opened study to assess the efficacy and safety of the withdrawal of nucleos/tide analogues in HIV-1-infected subjects with complete or intermediate resistance to these analogues, multitreated with virological suppression

Start Date26 Apr 2012

Sponsor / Collaborator-

NCT01352715

/ CompletedPhase 3IIT

Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)

The study was conducted on people who were taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), a type of anti-HIV drug) but the drugs in this regimen were not doing a good job of fighting their HIV infection.
The main purpose of this study was to compare two other anti-HIV drug regimens to see how well they fight HIV. The study also looked at how well participants tolerate the drug regimens and how safe they are.
The study was designed to determine whether taking the combination of lopinavir/ritonavir (LPV/r) plus raltegravir (RAL) works as well as what is usually used for second-line therapy: LPV/r plus the best-available nucleoside (nucleotide) reverse transcriptase inhibitor (NRTI) combination. Testing a regimen that does not include any NRTIs was important because NRTIs may no longer work for patients who received them as part of their first treatment regimen.

Start Date13 Mar 2012

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with Abacavir Sulfate/Lamivudine/Zidovudine

Login to view more data

100 Translational Medicine associated with Abacavir Sulfate/Lamivudine/Zidovudine

Login to view more data

100 Patents (Medical) associated with Abacavir Sulfate/Lamivudine/Zidovudine

Login to view more data

84

Literatures (Medical) associated with Abacavir Sulfate/Lamivudine/Zidovudine

01 May 2016·Medizinische Klinik, Intensivmedizin und NotfallmedizinQ4 · MEDICINE

Life-threatening cardiac arrhythmias due to drug-induced QT prolongation

Q4 · MEDICINE

Article

Author: Pfister, R ; Michels, G ; Kochanek, M

BACKGROUND:

Long QT syndrome (LQTS) can lead to ventricular arrhythmia, especially torsade de pointes (TdP) tachycardia and/or ventricular tachycardia (VT). The aim of this study is to characterize patients with life-threatening cardiac arrhythmias associated with drug-induced LQTS and to identify risk factors of distinct presenting arrhythmias.

MATERIAL AND METHODS:

In this retrospective study, we present 33 consecutive cases of life-threatening cardiac arrhythmias associated with drug-induced long QT, which were direct admitted as emergency to a medical intensive care unit (MICU) during an observational time of 6 years.

RESULTS:

Of 33 identified cases, 55 % presented with TdP with the need of resuscitation and 45 % showed nonsustained VT, respectively. In the total cohort the mean corrected QT interval (QTc) was 532 ± 29 ms, with 530 ± 31 ms (n = 14) in men and 533 ± 28 ms (n = 19) in women (p = 0.80), respectively. Cardiac drugs with QTc interval prolonging effect were reported in 24 % of cases, and the other 76 % involved noncardiac medications. Although hypokalemia is the most common risk factor for drug-induced malignant arrhythmias, a QTc interval of at least 500 ms seems to be the major determinant of the risk of drug-induced proarrhythmias. Interestingly, patients with TdP exhibit more bradycardia as such with VT.

CONCLUSIONS:

This is the first study of patients with drug-induced life-threatening cardiac arrhythmias who were admitted as a case of emergency to a MICU. Physicians should be aware of drug-induced LQTS and be able to identify patients at risk and avoid specific drugs in such patients.

01 Feb 2016·Proteomics. Clinical applicationsQ3 · BIOLOGY

¹⁸O proteomics reveal increased human apolipoprotein CIII in Hispanic HIV‐1+ women with HAART that use cocaine

Q3 · BIOLOGY

Article

Author: Suárez, Erick ; Jorge, Inmaculada ; Zenón, Frances ; Segarra, Annabell C. ; Vázquez, Jesús ; Meléndez, Loyda M. ; Serrano, Horacio ; Cruz, Ailed

Purpose:

Drug abuse is a major risk factor in the development and progression of HIV‐1. This study defines the alterations in the plasma proteome of HIV‐1‐infected women that use cocaine.

Experimental design:

Plasma samples from 12 HIV‐seropositive Hispanic women under antiretroviral therapy were selected for this study. Six sample pairs were matched between nondrug users and cocaine users. After IgG and albumin depletion, SDS‐PAGE, and in‐gel digestion, peptides from nondrug users and cocaine users were labeled with 16O and 18O, respectively, and subjected to LC‐MS/MS and quantitation using Proteome Discover and QuiXoT softwares and validated by ELISA.

Results:

A total of 1015 proteins were identified at 1% false discovery rates (FDR). Statistical analyses revealed 13 proteins with significant changes between the two groups, cocaine and noncocaine users (p < 0.05). The great majority pertained to protection defense function and the rest pertained to transport, homeostatic, regulation, and binding of ligands. Apolipoprotein CIII was increased in plasma of HIV+ Hispanic women positive for cocaine compared to HIV+ nondrug users (p ≤ 0.05).

Conclusions and clinical relevance:

Increased human apolipoprotein CIII warrants that these patients be carefully monitored to avoid the increased risk of cardiovascular events associated with HIV, HAART, and cocaine use.

01 Jul 2015·The Journal of antimicrobial chemotherapyQ2 · MEDICINE

Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database

Q2 · MEDICINE

Article

Author: Fagnani, Francis ; Yazdanpanah, Yazdan ; Raffi, François ; Lafuma, Antoine ; Laurendeau, Caroline ; Gourmelen, Julie

Abstract:

Objectives:

To compare adherence and persistence (continuous treatment with a prescribed medication) in HIV adult patients who received combination ART (cART) as a once-daily single-tablet regimen (STR) versus other administration schedules.

Methods:

A representative random sample of the French National Healthcare Insurance Database was used. Adherence and persistence were compared according to their administration schedules using χ2 and survival analyses. STRs were marketed in France in 2009 and the study period was selected to allow a sufficient number of patients with an STR and a relevant duration of follow-up.

Results:

During the period covered (2006–11), 362 HIV-positive adult antiretroviral-naive patients (566 lines of treatments) were selected. The mean rates of adherence were 89.6% for the STR (tenofovir/emtricitabine/efavirenz; n = 76), 86.4% for cART with >1 pill once daily (n = 242) and 77.0% for cART with >1 daily intake (n = 248; P < 0.0001 versus STR). Kaplan–Meier estimations of persistence after 2 years of treatment were 79.1% for the STR, 53.3% for cART with >1 pill once daily and 51.8% for cART with >1 daily intake (P = 0.001; log-rank test). Sensitivity analyses confirmed these results. After excluding treatment sequences showing a switch from tenofovir/emtricitabine plus efavirenz to the similar STR, the rates of persistence were 80.3% for the STR (n = 60), 77.3% for atazanavir-containing cART (n = 96) and 68.3% for darunavir-containing cART (n = 56) at 18 months (global P = 0.006).

Conclusions:

These results suggest that persistence is higher in HIV patients treated with an STR compared with other administration schedules. Significant benefit in terms of adherence was observed with the STR in comparison with regimens with >1 daily intake but no difference was observed when comparing with regimens involving >1 pill once daily.

100 Deals associated with Abacavir Sulfate/Lamivudine/Zidovudine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10838	Abacavir Sulfate/Lamivudine/Zidovudine	J05AR04	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	ViiV Healthcare Co.	14 Nov 2000

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00084149 (CTgov)	Phase 2	HIV Infections	54	Cyclosporine (Cyclosporine)	xuqaqgwwxn(uwlyqlaezj) = cduxrhsyqq eypebygfbt (nsmrrfpqfw, lcjxlbxymf - cbppyicovb) View more	-	13 Sep 2018
				Cyclosporine (No Cyclosporine)	xuqaqgwwxn(uwlyqlaezj) = leenebcfnf eypebygfbt (nsmrrfpqfw, bskaidlize - hyajddtfji) View more
NCT00270296 (CTgov)	Phase 2	HIV Infections	730	Lamivudine/Zidovudine+Lopinavir/Ritonavir	jowpdndgho = fukavgmltm irbfzkwoxn (obrzqxhotf, dnqhogqjeb - cramlocuny) View more	-	05 Jun 2017
NCT01352715 (A5273 \| SELECT, CTgov)	Phase 3	HIV Infections	515	Lopinavir/ritonavir+raltegravir (Arm A: LPV/r Plus RAL)	qjkmcqehwz = goveaiyhli jzdfothjye (jmppeszyas, rfnkxvxtjz - bsdjimdkwb) View more	-	06 Jan 2016
				Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs)	qjkmcqehwz = rengiujwiw jzdfothjye (jmppeszyas, nlyqtdqafd - fttmfeyfrj) View more
NCT00851630 (THIRST, CTgov)	Phase 4	Tuberculosis \| HIV Infections \| Immune Reconstitution Inflammatory Syndrome	70	Fixed dose combination zidovudine/lamivudine/abacavir (Early)	sovqjaloyx = tmhmugehug hnifutyhdu (vworfivtwi, jzyatmhxgx - icebzkhvwp) View more	-	08 Jan 2010
				Fixed dose combination zidovudine/lamivudine/abacavir (Delayed)	sovqjaloyx = fldkgfrnge hnifutyhdu (vworfivtwi, ukmykdvjqg - vtsdjjtwvl) View more
IAS2010	Not Applicable	AIDS-related Kaposi Sarcoma	23	Co-formulated abacavir/lamivudine/zidovudine	eqpvkqfabk(bucrfdgpzt) = zoglkmamdu wzjffguisr (pqsguvdztd )	-	01 Jan 2010
				Co-formulated abacavir/lamivudine plus co-formulated lopinavir/ritonavir	eqpvkqfabk(bucrfdgpzt) = lkshsmxliv wzjffguisr (pqsguvdztd )
DART trial (IAS2009)	Not Applicable	-	600	Combivir plus abacavir	kbdhnotoyw(hshqjdrnwn) = fndghsrbkr rnkwjxgnhz (uwfihjsiin )	Negative	01 Jan 2009
				Combivir plus nevirapine	kbdhnotoyw(hshqjdrnwn) = dmvdftujqi rnkwjxgnhz (uwfihjsiin )
IAS2007	Not Applicable	HIV Infections	54	Trizivir (TZV) plus tenofovir (TDF)	rxvuqujclf(ptrzygsqri) = usqhlgivti banejtuimc (fcxurjjmbq ) View more	-	01 Jan 2007
IAS2006	Not Applicable	HIV Infections	155	Trizivir-containing combination of antiretrovirals	afmclyzzhy(luicztnzyz) = drtkbmjksj bmdjfkzuuc (mrlphistmz, 99 - 370) View more	-	01 Jan 2006
IAS2006	Not Applicable	Maintenance	23	Trizivir/Kaletra	xnwroywdfp(sslpxfrqpp) = Drug-related AEs occurred in 13/23 subjects, with gastrointestinal disorders the most common (10/23) ounsaabqwr (fhvpbifabj ) View more	-	01 Jan 2006
				Trizivir
IAS2005	Not Applicable	-	51	Trizivir (TZV) + Tenofovir (TDF)	bksdkeqjhb(fabbcfhytf) = AEs leading to discontinuation were nausea, fatigue, and cancer cpjypmjqjp (ejrelujifp )	-	01 Jan 2005